This page shows the latest Xtandi news and features for those working in and with pharma, biotech and healthcare.
Pfizer/Astellas’ prostate cancer treatment Xtandi (enzalutamide) is also a prominent market competitor, with approvals in nmCRPC, mCSPC and metastatic castration-resistant prostate cancer (mCRPC).
Xtandi and Erleada have been fighting for dominance in the HSPC, which means that Nubeqa will have to prove its efficacy if it is to make a dent in this hotly ... In the phase 3 ARCHES trial, Xtandi in combination with ADT reduced the risk of cancer
Nubeqa will go head-to-head in the non-metastatic castration-resistant prostate cancer market with J&J’s Erleada (apalutamide), as well as Pfizer/Astellas’ Xtandi (enzalutamide).
Maintains a regulatory lead over rival Xtandi. Johnson &Johnson has clinched another approval for its prostate cancer drug Erleada in Europe, maintaining a regulatory lead over rival Xtandi from Astellas and ... Erleada can now be used for mCSPC patients
Johnson &Johnson’s Zytiga (abiraterone) or Pfizer’s Xtandi (enzalutamide).
Pfizer CEO Albert Bourla. Pfizer’s prostate cancer therapy Xtandi (enzalutamide) also grew in alliance revenues by 25% to $225m. ... For Pfizer, the potential approval in this indication could help drive Xtandi's growth even further – the drug picked
More from news
Approximately 30 fully matching, plus 44 partially matching documents found.
Analysts believe the drug could achieve peak sales of around $1.7bn, but will face fierce competition from the likes of Pfizer and Astellas’ established Xtandi. ... It also gives J&J a leg-up in what looks set to be a big market tussle with Pfizer and
35! Although Pfizer pointed to the $2.2bn of Xtandi sales for advanced metastatic prostate cancer, this product has been under licence to Astellas since 2009, including a US profit share ... Headline £m. Medivation (US). Pfizer (US). Company acquisition.
The prize of course is the one marketed product in Medivation's portfolio, Xtandi [enzalutamide for the treatment of advanced prostate cancer] with sales estimated to reach $1.5bn and already
Only one other deal had an upfront value of more than $1bn: the sale by UCLA to Royalty Pharma of its royalty rights to Xtandi with a cash payment of ... Research collaboration. $2, 258. UCLA/ Royalty Pharma. Xtandi – androgen receptor inhibitor.
Its efforts to date in oncology have seen it form a prostate cancer franchise on the back of Eligard (leuprolide acetate) and more recently Xtandi (enzalutamide). ... There it is currently conducting a series of investigations in breast cancer to assess
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi (enzalutamide).
Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).
Both men are veterans of Astellas. Dew joined the company in 2006 as senior manager business development and has worked on major products such as Xtandi.
She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche.
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...